Literature DB >> 19721054

Neutrophil CD64 expression in the diagnosis of local musculoskeletal infection and the impact of antibiotics.

S Tanaka1, J Nishino, T Matsui, A Komiya, K Nishimura, S Tohma.   

Abstract

We examined the usefulness of neutrophil CD64 expression in detecting local musculoskeletal infection and the impact of antibiotics on its expression. Of 141 patients suspected of musculoskeletal infection, 46 were confirmed by microbiological culture to be infected and 95 had infection excluded. The median CD64 count of patients with localised infection was 2230 molecules per cell (interquartile range (IQR) 918 to 4592) and that of the patients without infection was 937 molecules per cell (IQR 648 to 1309) (p < 0.001). The level of CD64 correlated with the CRP level in patients with infection, but not in those without infection (r = 0.59, p < 0.01). Receiver operator characteristic curve analysis revealed that CD64 was a good predictor of local infection. When the patients were subdivided into two groups based on the administration of antibiotics at the time of CD64 sampling, the sensitivity for detecting infection was better in those who had not received antibiotics. These results suggest that measurement of CD64 expression is a useful marker for local musculoskeletal infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19721054     DOI: 10.1302/0301-620X.91B9.22051

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  8 in total

1.  Neutrophil CD64: diagnostic accuracy and prognostic value in patients presenting to the emergency department.

Authors:  J Cid; G García-Pardo; R Aguinaco; R Sánchez; A Llorente
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-20       Impact factor: 3.267

2.  Utility of CD64 on Neutrophils in Orthopedic Infection.

Authors:  Akihiro Fujita; Shinji Tanishima; Yoshihiro Kato; Ryota Teshima; Hideki Nagashima
Journal:  Yonago Acta Med       Date:  2018-12-27       Impact factor: 1.641

3.  Analysis of Risk Factors and Association of Cluster of Differentiation (CD) Markers With Conventional Markers in Delayed Fracture Related Infection for Closed Fracture.

Authors:  Archana Raikwar; Ajai Singh; Vikas Verma; Abbas Ali Mehdi; Narendra Singh Kushwaha; Rashmi Kushwaha
Journal:  Cureus       Date:  2021-12-03

4.  CD64 as a potential biomarker in septic arthritis.

Authors:  Oddvar Oppegaard; Brita Skodvin; Anne-Kristine Halse; Nina Langeland
Journal:  BMC Infect Dis       Date:  2013-06-19       Impact factor: 3.090

5.  Normal sequential changes in neutrophil CD64 expression after total joint arthroplasty.

Authors:  Narutaka Katoh; Jinju Nishino; Keita Nishimura; Chisato Kawabata; Yuuko Hotta; Toshihiro Matsui; Shigeru Nakamura; Takashi Matsushita
Journal:  J Orthop Sci       Date:  2013-08-14       Impact factor: 1.601

6.  Monocyte HLA-DR expression and neutrophil CD64 expression as biomarkers of infection in critically ill neonates and infants.

Authors:  Justin E Juskewitch; Roshini S Abraham; Stacy C League; Sarah M Jenkins; Carin Y Smith; Felicity T Enders; Stefan K Grebe; William A Carey; W Charles Huskins
Journal:  Pediatr Res       Date:  2015-08-31       Impact factor: 3.756

7.  A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification.

Authors:  U Hassan; T Ghonge; B Reddy; M Patel; M Rappleye; I Taneja; A Tanna; R Healey; N Manusry; Z Price; T Jensen; J Berger; A Hasnain; E Flaugher; S Liu; B Davis; J Kumar; K White; R Bashir
Journal:  Nat Commun       Date:  2017-07-03       Impact factor: 14.919

8.  Differential Accumulation and Activation of Monocyte and Dendritic Cell Subsets in Inflamed Synovial Fluid Discriminates Between Juvenile Idiopathic Arthritis and Septic Arthritis.

Authors:  Maïlys Cren; Nadège Nziza; Aurélia Carbasse; Perrine Mahe; Emilie Dufourcq-Lopez; Marion Delpont; Hugues Chevassus; Mirna Khalil; Thibault Mura; Isabelle Duroux-Richard; Florence Apparailly; Eric Jeziorski; Pascale Louis-Plence
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.